Loading
A phase 3 trial of Cadonilimab and Cisplatin in cervical cancer, run by Akeso, active and no longer recruiting.
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer is a phase 3 interventional study registered as NCT05235516 by Akeso, with 636 participants enrolled, started 2022-06-21 and due to reach its primary completion in 2026-05. Interventions recorded: AK104, EBRT, BT, cisplatin and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Locally advanced cervical cancer, Cervical cancer and the tag pipeline.
Shares Locally advanced cervical cancer, Cervical cancer and the tag pipeline.
Shares Akeso, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Cadonilimab, Bispecific antibodies, Immune checkpoint inhibitors and the tag pipeline.
Shares Akeso, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/